(株)デ・ウエスタン・セラピテクス研究所の貸借残高情報
| 主市場 | 業種 | 証券コード/EDINET | 英名称 |
|---|---|---|---|
| 東証GRT | 医薬品 | 4576/E22024 | D.Western Therapeutics Institute, Inc. |
| 公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
|---|---|---|---|---|---|---|---|---|---|
| 2013/03/08 | 日証協 | 32,500株 | -18.14% | 309,600株 | +2318.75% | 151,010株 | -8.43% | 320,900株 | +367.1% |
| 2013/03/01 | 日証協 | 39,700株 | -17.63% | 12,800株 | 0% | 164,911株 | +15.64% | 68,701株 | +73.49% |
| 2013/02/22 | 日証協 | 48,200株 | -25.73% | 0株 | -100% | 142,610株 | +1.28% | 39,600株 | +2.06% |
| 2013/02/15 | 日証協 | 64,900株 | +104.09% | 34,300株 | +106.63% | 140,810株 | +15.03% | 38,800株 | +35.9% |
| 2013/02/08 | 日証協 | 31,800株 | -66.1% | 16,600株 | -38.06% | 122,410株 | -15.57% | 28,550株 | -68.83% |
| 2013/02/01 | 日証協 | 93,800株 | +32.49% | 26,800株 | +92.81% | 144,980株 | +36.8% | 91,600株 | +348.58% |
| 2013/01/25 | 日証協 | 70,800株 | -15.61% | 13,900株 | 0% | 105,980株 | -6.1% | 20,420株 | -16.99% |
| 2013/01/18 | 日証協 | 83,900株 | -20.1% | 0株 | 0% | 112,860株 | -16.06% | 24,600株 | +60.78% |
| 2013/01/11 | 日証協 | 105,000株 | -15.66% | 0株 | 0% | 134,460株 | -20.93% | 15,300株 | +9999.99% |
| 2013/01/04 | 日証協 | 124,500株 | 0% | 0株 | 0% | 170,060株 | +3.03% | 100株 | -98.68% |
| 2012/12/28 | 日証協 | 124,500株 | 0% | 0株 | -100% | 165,060株 | -2.42% | 7,600株 | +1.33% |
| 2012/12/21 | 日証協 | 124,500株 | +4.1% | 4,900株 | 0% | 169,160株 | +4.06% | 7,500株 | +177.78% |
| 2012/12/14 | 日証協 | 119,600株 | -1.97% | 0株 | 0% | 162,560株 | -7.82% | 2,700株 | -87.56% |
| 2012/12/07 | 日証協 | 122,000株 | 0% | 0株 | 0% | 176,360株 | +8.89% | 21,700株 | +768% |
| 2012/11/30 | 日証協 | 122,000株 | 0% | 0株 | 0% | 161,960株 | -0.09% | 2,500株 | -51.46% |
| 2012/11/22 | 日証協 | 122,000株 | 0% | 0株 | -100% | 162,110株 | +2.53% | 5,150株 | +758.33% |
| 2012/11/16 | 日証協 | 122,000株 | -9.23% | 25,000株 | -7.41% | 158,110株 | -5.84% | 600株 | -98.15% |
| 2012/11/09 | 日証協 | 134,400株 | 0% | 27,000株 | 0% | 167,910株 | -1% | 32,500株 | +9999.99% |
| 2012/11/02 | 日証協 | 134,400株 | -2.82% | 0株 | -100% | 169,610株 | -4.56% | 200株 | -97.18% |
※株式分割は考慮していませんのでご注意ください。